None
Quote | Cornerstone Strategic Value Fund Inc. (NYSE:CLM)
Last: | $7.25 |
---|---|
Change Percent: | 0.0% |
Open: | $7.23 |
Close: | $7.25 |
High: | $7.29 |
Low: | $7.23 |
Volume: | 807,849 |
Last Trade Date Time: | 11/28/2023 03:00:00 am |
News | Cornerstone Strategic Value Fund Inc. (NYSE:CLM)
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5 Million Upfront, the Potential for Additional $77.5 Million in Clinical, Regulatory, a...
ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D.,...
Message Board Posts | Cornerstone Strategic Value Fund Inc. (NYSE:CLM)
Subject | By | Source | When |
---|---|---|---|
Anyone know about the upcoming$ CLM & $CFP | towerclimber92 | investorshub | 04/07/2015 7:20:28 AM |
Fluctuates? You mean steadily declines because the payout | bar1080 | investorshub | 01/21/2015 3:34:50 AM |
IMO it's still pays out good from divi. | globalprince | investorshub | 01/07/2015 11:30:08 PM |
Yuck. The only reason I was interested in | towerclimber92 | investorshub | 01/07/2015 11:14:52 PM |
Yeah it did | globalprince | investorshub | 01/07/2015 9:00:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Cornerstone Strategic Value Fund Inc. Company Name:
CLM Stock Symbol:
NYSE Market:
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5 Million Upfront, the Potential for Additional $77.5 Million in Clinical, Regulatory, a...
ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D.,...
ALPHARETTA, Ga., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that multiple oral and poster present...